Neoplasms

All Conditions

Digestive System Diseases

Nutritional and Metabolic Diseases

Rare Diseases

Carcinoma

Carcinoma, Squamous Cell

Esophageal Neoplasms

Malnutrition

Esophageal Squamous Cell Carcinoma

Gastrointestinal Neoplasms

Digestive System Neoplasms

Head and Neck Neoplasms

Gastrointestinal Diseases

Esophageal Diseases

Esophageal Cancer

Antineoplastic Agents

All Drugs and Chemicals

Nimotuzumab

Antineoplastic Agents, Immunological

Radiotherapy,40-50.4Gy/20-28f. Nimotuzumab 400mg,ivgtt,W2d. Chemotherapy, S-1,40-60mg/m2, on BSA, orally twice daily on radiotherapy days.

Nimotuzumab with chemoradiotherapy

Xin Wang, Doctor

Guojie Feng, B.M

Elderly or malnourished patients diagnosed with locally advanced esophageal squamous cell carcinoma (ESCC) had poor prognosis. Radiotherpy was an important and effective treatment in treating ESCC. The present study is a one-arm trial that seeks to evaluate the efficacy in patients with unresectable ESCC. The study objectives include R0 resection rate, complete pathological response and treatment toxicity, etc.

Nimotuzumab is a recombinant humanized monoclonal antibody against EGFR. Its efficacy and safety in patients with esophageal cancer have been confirmed by many studies.

The current prospective phase II study aimed to evaluate the efficacy and safety of a combination regimen comprising chemotherapy with nimotuzumab with a dose of 800mg per week and S-1 and concurrent radiotherapy for patients who are elderly or malnourished.

Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients

Nimotuzumab Concurrent With Chemoradiotherapy for Elderly or Malnourished Patients With Unresectable Esophageal Squamous Cell Carcinoma: A Phase II Study

Minimal distance tumor/circumferential resection margin (CRM) \> 1 mm.

the complete remission of all viable cancer cells in any of the specimens from surgery, including the primary site and lymph nodes

the time from start of chemoradiotherapy to 1 month after chemoradiotherapy

the time from start of induction chemo(immuno)therapy to all-cause death, or the last day of follow-up

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Principal Investigator

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Neoplasms, Squamous Cell

Radiotherapy, 40-50.4Gy/20-28f. Nimotuzumab 400mg, ivgtt, W2d. Chemotherapy, S-1, 40-60mg/m2, on BSA，orally twice daily on radiotherapy days.

Xin Wang, doctor

Patients diagnosed with locally advanced esophageal squamous cell carcinoma (ESCC) who failed to induction chemo(immuno)therapy had poor prognosis. Radiotherpy was an important and effective treatment in treating ESCC. The present study is a one-arm trial that seeks to evaluate the efficacy in patients with unresectable ESCC. The study objectives include R0 resection rate, complete pathological response and treatment toxicity, etc.

Nimotuzumab is a recombinant humanized monoclonal antibody against EGFR. Its efficacy and safety in patients with esophageal cancer have been confirmed by many studies.

The current prospective phase II study aimed to evaluate the efficacy and safety of a combination regimen comprising chemotherapy with nimotuzumab and S-1 and concurrent radiotherapy for patients who are not sensitive to induction chemo(immuno)therapy.

Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma

Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma After Failure of Chemotherapy：A Phase II Study

the time from start of induction chemo(immuno)therapy to progression, relapse, all-cause death, or the last day of follow-up

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients	NCT06429839	Esophageal Canc... Nimotuzumab Chemoradiothera... Chemotherapy Immunotherapy	Nimotuzumab wit...	18 Years - 80 Years	Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma	NCT06410651	Esophageal Canc... Nimotuzumab Chemoradiothera... Chemotherapy Immunotherapy	Nimotuzumab wit...	18 Years - 80 Years	Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients	NCT06429839	Esophageal Canc... Nimotuzumab Chemoradiothera... Chemotherapy Immunotherapy	Nimotuzumab wit...	18 Years - 80 Years	Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Spots Global Cancer Trial Database for nimotuzumab with chemoradiotherapy